DAKLINZA (E.R. Squibb & Sons, L.L.C.)
Welcome to the PulseAid listing for the DAKLINZA drug offered from E.R. Squibb & Sons, L.L.C.. This Hepatitis C Virus NS5A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | E.R. Squibb & Sons, L.L.C. |
| NON-PROPRIETARY NAME: | daclatasvir |
| SUBSTANCE NAME: | DACLATASVIR DIHYDROCHLORIDE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Hepatitis C Virus NS5A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2016-05-18 |
| END MARKETING DATE: | 0000-00-00 |
DAKLINZA HUMAN PRESCRIPTION DRUG Details:
| Item Description | DAKLINZA from E.R. Squibb & Sons, L.L.C. |
| LABELER NAME: | E.R. Squibb & Sons, L.L.C. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 90(mg/1) |
| START MARKETING DATE: | 2016-05-18 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0003-0011_37ce5129-6591-4b3f-b8dc-aad593664c37 |
| PRODUCT NDC: | 0003-0011 |
| APPLICATION NUMBER: | NDA206843 |
Other DACLATASVIR DIHYDROCHLORIDE Pharmaceutical Manufacturers / Labelers:
